Cytokinetics Inc (CYTK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.82B
Last updated: Nov 17, 2026 at 11:04 AM ET
Cytokinetics Inc (CYTK) Stock Forecast
Analysts expect Cytokinetics (CYTK) to earn -$5.76 per share in the fiscal year ending Dec 31, 2026, on revenue of $164.56M. Of 22 analysts, 20 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 8 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 7 | 31.8% |
| Buy | 13 | 59.1% |
| Hold | 2 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 22
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 169.3%.
- Fiscal year ending Dec 31, 2026
- -$5.76
- EPS consensus, revenue $164.56M
- Fiscal year ending Dec 31, 2027
- -$4.23
- EPS consensus, revenue $443.13M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.76 | -$6.27 to -$4.64 | 17 | $164.56M | $151.50M to $223.66M | 18 |
| Dec 31, 2027 | -$4.23 | -$5.71 to -$2.89 | 17 | $443.13M | $316.80M to $594.89M | 20 |
Quarterly Estimates
The EPS consensus rises from -$1.44 for the quarter ending Dec 31, 2026 to -$1.28 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.44 | -$1.58 to -$0.98 | 24 | $66.72M | $51.92M to $86.57M | 22 |
| Mar 31, 2027 | -$1.28 | -$1.55 to -$0.73 | 6 | $75.29M | $56.44M to $95.40M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 20 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 8 | 2 |
| Fiscal year ending Dec 31, 2027 | 9 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.97.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.76 | -$5.88 | -$5.94 | -$5.94 | -$5.97 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.23 | -$4.40 | -$4.44 | -$4.45 | -$4.43 | N/A |
| Quarter ending Mar 31, 2027 | -$1.28 | -$1.32 | -$1.34 | -$1.34 | -$1.28 | N/A |
Frequently Asked Questions About CYTK
What is the CYTK stock forecast?
Consensus analyst estimates put Cytokinetics's EPS at -$5.76 for the fiscal year ending Dec 31, 2026, on revenue of $164.56M. The consensus rating from 22 analysts is Buy.
How do analysts rate CYTK stock?
Of 22 analysts covering Cytokinetics, 7 rate it Strong Buy, 13 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CYTK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.76, with estimates from -$6.27 to -$4.64 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.23, with estimates from -$5.71 to -$2.89 from 17 analysts.
What revenue do analysts expect from Cytokinetics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $164.56M, with estimates from $151.50M to $223.66M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $443.13M, with estimates from $316.80M to $594.89M.
How many analysts cover CYTK?
22 analysts rate Cytokinetics stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CYTK pages: Overview, Earnings, Forecast, Financials, Competitors